FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.
What happened
FDA inspected Unipack LLC's drug manufacturing facility from June 11 to June 30, 2025. FDA found inadequate investigations of out-of-specification (OOS) results and unknown peaks in lab test charts, incomplete and non-contemporaneous laboratory records, weak electronic data controls, and release specifications missing USP-required tests for suppositories.
What FDA found
Unipack did not thoroughly investigate out-of-specification (OOS) results and unknown peaks, invalidated OOS results without identified lab error, and released batches without root cause or corrective action.
21 CFR 211.192Laboratory records were incomplete or not recorded at the time of testing, including undated sample preparations and high-performance liquid chromatography (HPLC) injections with no processed results or notebook entry.
21 CFR 211.194(a)Analysts had administrator rights that allowed alteration or deletion of lab data and files, and deleted-system errors were not assessed.
21 CFR 211.194(a)Analysts manually adjusted HPLC peak integration without scientific justification or procedural controls.
21 CFR 211.194(a)Release specifications for suppositories omitted USP-required identification and assay tests, and multiple batches were distributed since March 2022 without those tests.
21 CFR 211.160(b)
What FDA wants
FDA tells Unipack to correct the violations promptly and respond in writing within 15 working days with corrective actions and plans, including independent assessments and remediation for its investigations, corrective and preventive action (CAPA) program, laboratory controls, and data integrity.
Who should pay attention
- companies that buy or distribute Unipack-made drugs
- contract manufacturers and testing labs with similar data controls
- quality units overseeing suppository products
This is a summary. Read the original letter on fda.gov.